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Abstract: The Netherlands and Germany are neighbouring countries within the European Union but
are differently affected by multidrug-resistant microorganisms (MDRO). In this narrative review, we
summarize data about antibiotic use, the occurrence of MDRO and healthcare-associated infections
in these two countries, as well as data about organizational and structural differences between the
Dutch and German healthcare systems. These results are discussed with a focus on whether or how
the organization of healthcare influences MDRO prevention. We found that from the point of view of
MDRO prevention, a higher density of inpatient care, a higher number of hospitals, a longer length of
stay and lower staffing ratios might facilitate MDRO dissemination in German hospitals.
Keywords: antimicrobial resistance; Euregio; MRSA; ESBL; MDRO; infection prevention;
antibiotic use
1. Introduction
The Netherlands and Germany are neighbouring countries in the European Union sharing a 567
km border. The two countries are strongly interconnected on a historical, cultural, economic, legislative
and social level. However, from the perspective of infection prevention and control (IPC) specialists,
there are major differences between these two countries when comparing rates of multidrug-resistant
microorganisms (MDRO). The question is how these differences can be explained.
Typical reasons for the failure of MDRO-related IPC measures are shown in Figure 1. Many of
these factors are structural aspects, which have their roots in the structures of different healthcare
systems, and which are hard to influence by IPC experts in single hospitals. In addition, sources of
MDRO outside the healthcare system might also impact the dissemination of these pathogens.
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Figure 1. Typical reasons for the failure of infection and control of multidrug-resistant 
microorganisms (MDRO). 
Hence, in this narrative review we aimed to (1) describe the differences in the occurrence of 
MDRO, healthcare-associated infections (HAI) and antibiotic use between the Netherlands and 
Germany; (2) summarize data elucidating the structure the healthcare systems in these two countries 
and (3) to interpret both data from the point of view of IPC specialists. 
2. Multidrug-Resistant Microorganisms, Antibiotic Use and Healthcare-Associated Infections in 
The Netherlands and Germany 
2.1. Data about the Occurrence of MDRO 
Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) on the 
proportion of MDRO among clinically relevant pathogens isolated from invasive infections indicate 
that, overall, Germany seems to have a bigger challenge than the Netherlands (Figure 2). In 
consequence, a recent study estimated that the burden of MDRO-infections described by the 
numbers, deaths, incidences and mortality rates are also divergent (Table 1, [1]). 
Figure 1. Typical reasons f r the failur o infection and control of multidrug-resistant mic oorganisms
(MDRO).
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healthcare-associated infections (HAI) and antibiotic use etween The Netherlands and Germany;
(2) summarize data elucidating the structure the healthcare systems in these two countries and (3) to
interpret both data from the point of view of IPC specialists.
2. Multidrug-Resistant Microorganisms, Antibiotic Use and Healthcare-Associated Infections in
The Netherlands and Germany
2.1. Data about the Occurrence of MDRO
Data from the European Antimicrobial Resistance Surveillance Network (EARS-Net) on the
proportion of MDRO among clinically relevant pathogens isolated from invasive infections indicate
that, overall, Germany seems to have a bigger challenge than The Netherlands (Figure 2). In
consequence, a recent study estimated that the burden of MDRO-infections described by the numbers,
deaths, incidences and mortality rates are also divergent (Table 1, [1]).
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Figure 2. Percentage of resistant isolates from bloodstream infections according to EARS-Net data 
2009-2018. (a) for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococcus faecium (VRE); (b) for third-generation cephalosporin-resistant Escherichia coli, 
carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Acinetobacter spp. 
Table 1. Estimated median number of cases (incidences per 100,000 inhabitants) and median 
numbers of deaths (mortality per 100,000 inhabitants) for infections due to MDRO in 2015 [1]. 
Pathogen * 
Germany Netherlands 
Cases  
(incidence) 
Deaths  
(mortality) 
Cases  
(incidence) 
Deaths  
(mortality) 
CRAB 278 (0.34) 24 (0.03) 14 (0.08) 1 (0.01) 
VRE 3089 (3.80) 206 (0.25) 63 (0.37) 4 (0.02) 
CRKP 125 (0.15) 3 (0) 0 (0) 0 (0) 
MRSA 13684 (16.85) 653 (0.80) 249 (1.47) 12 (0.07) 
3rd generation-cephalosporin-res. E. coli 28392 (34.97) 868 (1.07) 3503 (20.73) 107 (0.63) 
all assessed MDROs  54509 (67.13) 2363 (2.91) 4982 (29.48) 206 (1.22) 
* Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium 
(VRE), carbapenem-resistant Klebsiella pneumoniae (CRKP) and carbapenem-resistant Acinetobacter 
baumannii (CRAB). 
  
Figure 2. Percentage of resistant isolates from bloodstream infections according to EARS-Net data
2009-2018. (a) for methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant
Enterococcus faecium (VRE); (b) for third-generation cephalosporin-resistant Escherichia coli,
carbapenem-resistant Klebsiella pneumoniae and carbapenem-resistant Acinetobacter spp.
Table 1. Estimated median number of cases (incidences per 100,000 inhabitants) and median numbers
of deaths (mortality per 100,000 inhabitants) for infections due to MDRO in 2015 [1].
Pathogen *
Germany The Netherlands
Cases
(Incidence)
Deaths
(Mort lity)
Cases
(Incidence)
Deaths
(Mor ality)
CRAB 278 (0.34) 24 (0.03) 14 (0.08) 1 (0.01)
VRE 3089 (3.80) 206 (0.25) 63 (0.37) 4 (0.02)
CRKP 125 (0.15) 3 (0) 0 (0) 0 (0)
MRSA 13,684 (16.85) 653 (0.80) 249 (1.47) 12 (0.07)
3rd generation-cephalosporin-res. E. coli 28,392 (34.97) 8 (1.07) 3503 ( . 107 (0.63)
all assessed MDROs 54,509 (67.13) 2363 (2.91) 4982 (29.48) 206 (1.22)
* Methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE),
carbapenem- esista t Klebsiella pneumonia (CRKP) and carbapenem-resistant Acinetobacter baumannii (CRAB).
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2.2. Data about HAI
The rate of HAI was recently assessed in an EU-wide study: in Germany, the prevalence of
nosocomial infections was 5% (3.8–67, n = 516 infections, 46 participating hospitals) vs. 7.4% in
The Netherlands (6.2–8.8, n = 598 infections in 33 participating hospitals) [2]. However, a continuous
surveillance system established in The Netherlands yielded different results: in 33 hospitals, the overall
prevalence of HAI was 4.6% in 2018 [3].
In 2018, the incidence of Clostridioides difficile-associated infections (CDI) was 3.17/10,000
patient-days in 24 Dutch hospitals participating in a surveillance system compared with 5.47/10,000
patient-days in 571 German hospitals [4,5]. The locations of the onset were healthcare facilities in 54%
of the cases on the Dutch and 56% on the German side of the border [4,5].
The use of diagnostics might also affect HAI rates. A recent study evaluated the quality of
microbiological diagnostics of bloodstream infections among European countries [6]. According to this
study, 21.6 blood culture (BC) sets per 100 hospitalizations were sampled in German (n = 10 laboratories)
hospitals. Due to the relatively small number of participating laboratories from The Netherlands
(n = 6), the respective Dutch data were not analyzed in the original publication. Re-assessing these
data, 33 BC sets per 100 hospitalizations were sampled in The Netherlands (personal communication,
E. A. Idelevich, Münster and K. Becker, Greifswald). In the overall analysis of 162 laboratories from all
countries included in the survey, 18.9 BC sets per 100 hospitalisations were taken.
2.3. Data about Antibiotic Use
In 2017, the use of antibiotics among outpatients (in primary care) was 10.1 defined daily doses
(DDD) per 1000 inhabitants in The Netherlands vs. 13.7/1000 in Germany [7]; i.e., about 33% higher.
Prescribing data showed that different prescribing habits were observed especially for the group of
other betalactam antibiotics, i.e., predominantly oral cefuroxime (Table 2).
Table 2. Antibiotic use among outpatients in defined daily doses (DDD) per 1000 inhabitants per day
in 2017 [7].
Type of Antibiotic EU-Mean Germany The Netherlands
Total use 21.8 13.7 10.1
Penicillins 11.5 5.0 4.0
Other betalactams 2.0 2.8 0
Sulfonamide/trimethoprim 0.6 0.5 0.4
Macrolides 2.9 2.1 1.4
Tetracyclines 2.2 1.8 2.0
Quinolones 1.6 1.1 0.7
Other antibiotics 1.1 0.5 1.5
In 2016, both national surveillance systems described that the density of antibiotic use in hospitals
was 84 DDD/100 patient-days in The Netherlands (n = 62 participating hospitals; with large variation
for general hospitals; overall use in general hospitals was 82.5 DDD/100 patient-days and in university
hospitals 92.5 DDD/100 patient-days) [8] vs. 52.5 DDD/100 patient-days in Germany (n = 148
participating hospitals; in larger and maximum care hospitals use was 57.3 DDD/100 patient-days) [9].
Qualitatively, the densities for the use of penicillins, first and third generation cephalosporins,
aminoglycosides, glycopeptides and fluoroquinolones were higher in Dutch hospitals, while the
densities of use for second generation cephalosporins and macrolides were lower compared with
German hospitals (Figure 3).
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Figure 3. Antibiotic use in defined daily doses (DDD) per 100 patient-days for antibiotics belonging to
the J01 category according to the ATCC classification system [8].
3. Data about Healthcare Structures in The Netherlands and Germany
Table 4 compares data about the numbers of hospitals, the density of hospital-use, as well as
staffing levels in German and Dutch hospitals.
Table 3. Structures of the healthcare systems in The Netherlands and Germany [10,11].
Indicator The Netherlands Germany
Population 16,979,140 82,175,684
Health expenditures in Mio. € 72,788.63 351,7 1.00
Pro inhabitant in € 3,885 4,160
Life expectancy at birth (years) 81.7 81.0
Length of hospital tay (curative care) in days 5.0 7.5
Hospital days per year 8,268165 146,048,193
per 1,000 inhabitants 486.96 1777.27
Hospital beds total (curative, rehabilitative,
long-term care) 61,767 663,941
Curative 51,176 498,718
rehabilitative 1946 165,223
per 1000 inhabitants 3.64 8.08
Hospital beds/100,000 inhabitants curative care 301 606
B d occupancy rate (curative care) 66% 80%
Hospital discharges 1,649,905 19,480,503
Per 1000 inhabitants 97.17 237.06
Hospital personnel (full-time equivalents) 198,670 988,000
per 100 patient-days 2.40 0.68
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Table 4. Structures of the healthcare systems in The Netherlands and Germany [10,11].
Indicator The Netherlands Germany
Physicians 21,808 166,000
per 100 patient-days 0.26 0.11
Qualified nurses/midwives 58,489 341,000
per 100 patient-days 0.71 0.23
Nursing associates 11,563 34,000
per 100 patient-days 0.14 0.02
Antibiotic Stewardship Teams
1 team * per hospital
mandatorily
1 FTE per 500 beds
recommended *
Selected interventions per 100,000 inhabitants
cataract-surgery 1014 1041
appendectomies 96 155
Transluminal coronary angioplasty (PTCA) 234 406
% of 1-day interventions (day-patients, outpatients)
cataract-surgery 99.6% 82.5%
tonsillectomies 68.4% 4.0%
Inguinal hernia 80.2% 0.3%
* In NL: Including medical microbiologist, infectious disease specialist, pharmacist; in Germany: FTE =
full-time equivalent (additionally further FTEs for special departments); recommended in antibiotic stewardship
guideline [12], but not mandatory for all hospitals. On the level of German federal states, some states start setting
mandatory standards.
4. Discussion
In this review, we tried to put the occurrence of MDRO in relation to existing data about healthcare
structures in The Netherlands and Germany. Table 4 shows that the financial resources used in the
Dutch and German healthcare systems are similar. However, the density of inpatient-care is much
higher in Germany, as indicated by the facts that there are 2.2-times more hospital beds and 2.4-times
more discharges per population. In addition, the rate of ambulatory surgery is lower for many elective
interventions and the rates of hospital-days per 1000 inhabitants as well as the average length of stay
are higher in Germany. At the same time, the density of hospital personnel (i.e., the staffing level per
100 hospital days) is 3.5-times higher in hospitals in The Netherlands, especially for nursing staff.
Hence, from an IPC perspective, German hospitals are clearly challenged by more patients, who
are hospitalized for a longer period, but cared for by fewer personnel. Overall, the effects of these
structures remain controversial and highly speculative. However, it is clear that these structures have
a major impact on several aspects related to MDRO prevention:
1. Hospitalization (number of cases, length of stay) per se increases the risk of MDRO transmission
(from patient-to-patient, via healthcare workers or via surfaces). Moreover, due to the higher
number of hospitals in Germany, many hospitals are less specialized. Consequently, there is more
patient traffic between different hospitals (as patients are sent from basic care to more specialized
hospitals). In this setting, each admission bears the possibility of inter-institutional transmission,
facilitating regional dissemination of MRDO. Some studies have demonstrated that this led to a
clonal expansion of some MDRO [13,14].
2. Hand hygiene must be performed more rigorously in German hospitals. Due to fewer personnel
and more patients, there are more contacts per individual healthcare worker. In addition, one
healthcare worker has contact with more patients. If it is assumed that the compliance level with
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hand hygiene is similar in The Netherlands and Germany, these underlying structures might
facilitate the transmission of MDRO. Moreover, a high awareness about the AMR problem among
healthcare workers has been recently shown for both countries [15].
3. Although the density of hospital beds is higher in Germany, the bed occupancy rate is also
higher than in The Netherlands. While in German hospitals occupancy rates are regularly above
80%, they are usually around 60%-70% in Dutch hospitals (Table 4). This has an impact on
the availability of single rooms for isolation. Besides the rather low scientific evidence for the
isolation of patients with MDRO and the lack of randomized trials regarding this issue [16], as
well as the potential disadvantages of “isolated care” in single-rooms (e.g., stigmatization and less
awareness), many clinicians and hospital administrations in Germany refer to a lack of isolation
beds and financial penalties due to blocked beds, when arguing against single-room isolation.
In The Netherlands, due to the structural difference, single-room isolation is easier to organize
and rather undisputed for most MDROs including methicillin-resistant Staphylococcus aureus,
vancomycin-resistant enterococci, multidrug-resistant Gram-negative bacteria (including even
extended-spectrum betalactamase-producing, carbapenem-susceptible Enterbacteriaceae). For risk
patients, the concept of pre-emptive isolation at admission as long as screening results are pending,
is also a key component of Dutch IPC recommendations. In Germany, pre-emptive isolation is
performed for patients with a high risk of carriage of carbapenem-resistant Enterobacteriaceae
or Acinetobacter baumannii or for patients with a very high risk of MRSA carriage (e.g., known
carriage from previous hospitalizations). However, for MRSA, the fact that >30% of patients at
admission are risk patients in Germany, prevents the ability to use pre-emptive isolation for all
patients at risk [17].
However, a causal relationship between healthcare structures and prevalence of MDRO is rather
difficult to prove. This is partly because of the available contradictory data. For example, the prevalence
of HAI, such as urinary-tract infections or catheter-related bloodstream infections, seem to be similar in
the two countries [2,3]. For certain surgical site infections, up to three times more infections have been
described in The Netherlands compared to Germany [2]. This seems in contrast to the theory that more
staff facilitate hand hygiene compliance, as hand disinfection is regarded as one of the cornerstones
of HAI prevention. Hence, as we are not aware of any structured investigations assessing hand
hygiene indications and compliance rates in the border region, such assessments should be stimulated.
However, on a population level, the higher density of care in Germany (more hospitalizations, more
hospital-days per patient) vs. the Dutch healthcare system characterized by waiting lists for certain
elective procedures and stricter prioritization, might increase the rate of HAIs per inhabitants in
Germany. Clear data is lacking regarding this issue.
The prudent use of antibiotics is a public health priority. In The Netherlands, antibiotic use among
outpatients is about 30% lower than in Germany. The reasons have not been studied in detail, but
could involve both educational and socio-cultural aspects (e.g., attitude towards prescribing antibiotics,
expectations of patients etc.) [18,19]. One example is the dissimilar use of oral cefuroxime in these
two countries (Table 2). Oral cefuroxime has a lower resorption when given orally and a rather high
selection pressure for MDRO. In a study, performed in the Dutch—German border region it was
demonstrated that the proportion of children in ambulatory care, who received at least one antibiotic
within a one-year period was 29.8% in The Netherlands and 38.9% in Germany. In this study, oral
cefuroxime accounted for 25% of the prescriptions in Germany and 0.1% in The Netherlands [20].
While the data for outpatients clearly indicate less selection pressure in The Netherlands and are
a good argument for less MDRO, we found that the density of antibiotic use measured in DDD/100
patient-days in Dutch hospitals is higher than in German hospitals (Figure 3). This is true for
general hospitals as well as larger teaching hospitals. We are unsure to what extent this is a virtual
difference, which could be explained by the shorter length of stay in Dutch hospitals (when using
patient-days as the denominator) or by the more extensive use of penicillins in Dutch hospitals
(when actually prescribed doses of penicillins are much higher than the WHO-defined DDD). On the
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other hand, the more frequent use of 3rd generation cephalosporins seems reasonable, as selective
digestive decontamination for pneumonia-prevention is rarely performed in German, but often in
Dutch hospitals. Moreover, for fluoroquinolones, the DDD describes the actual daily dose used in
clinical care more accurately than for penicillins. Hence, the reason for the substantially higher use
of fluoroquinolones in Dutch hospitals remains unclear. Overall, these discrepancies point out that
studies assessing the antibiotic use in Dutch and German hospitals in a more detailed manner (e.g.,
on wards treating matched patient-collectives such as intensive care units) should be inspired. This
should also help to explain why despite the higher density of antibiotic use, data about the occurrence
of nosocomial C. difficile-associated infections indicate that antibiotic selection pressure might be lower
in Dutch hospitals.
Assessing the number of blood culture sets (BCs) related to patient-days could be a quality
indicator for microbiological diagnostics. More BCs are sampled in Netherlands than in Germany,
but for both countries, BC rates were higher than the average for European countries [6]. However,
the interpretability of this parameter when assessed for complete hospitals might be very limited, if
the types of hospitals and hospital-departments included in the analysis differ or are even undefined.
Representative data that would allow for a more robust comparison, such as BC rates among patients on
intensive care units, are currently available only for German ICUs indicating a high rate of diagnostics
(mean 170 BC sets/1000 patients-days, [21]).
However, formally it is a clear advantage that in The Netherlands there are mandatory regulations
for antibiotic and diagnostic stewardship staff including microbiologists, infectious disease specialists
and pharmacists. Such regulations are currently on the way in Germany, but respective scientific
recommendations have not reached the level of legal liability.
In both countries, sources for MDRO outside healthcare facilities have been studied extensively.
It was found that regionally livestock-associated MRSA play a major role for colonization and
infections for those persons who are directly exposed to livestock [22,23]. In addition, ESBL-producing
Enterobacteriaceae (ESBL-E) from food items have been demonstrated to be responsible for only a
minority of ESBL-E infections among humans [24,25]. Antibiotic use among livestock was markedly
reduced (by more than 50%) in both countries [26]. Hence, there is no evidence that there are major
differences in the control of sources for MDRO outside healthcare facilities. However, the differences
in outpatient antibiotic use mentioned above may contribute to more selection pressure and a higher
probability for the emergence of MDRO in the community in Germany.
Overall, one major limitation should be mentioned. While for some indicators, such as antibiotic
resistance rates or antibiotic use among outpatients, data are available from international surveillance
networks using a defined technique, other indicators used in this review are from national surveillance
programs or studies. Of course, both of these different data sources might cause biases when comparing
The Netherlands and Germany (e.g., different representativeness of the data source for the country,
slightly different assessment techniques). However, we carefully checked the included sources and
pointed out where data sources might have caused a major bias.
5. Conclusions
Although regional IPC measures have been proven as a promising strategy [27,28], the various
healthcare structural aspects that can hardly be influenced by local IPC specialists must also be
recognized. Those IPC factors include differences of reimbursement systems, staffing levels, hospital
or healthcare densities and antibiotic use between The Netherlands and Germany.
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